trending Market Intelligence /marketintelligence/en/news-insights/trending/3pa0XWVReFZMiIBGC_qbEQ2 content esgSubNav
In This List

Arcline Investment Management acquires majority stake in Akron Biotechnology

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Podcast

Street Talk Episode 87

Blog

A New Dawn for European Bank M&A Top 5 Trends

Blog

Insight Weekly: US banks' loan growth; record share buybacks; utility M&A outlook


Arcline Investment Management acquires majority stake in Akron Biotechnology

Private equity firm Arcline Investment Management LP completed the purchase of a majority stake in Akron Biotechnology LLC, a Boca Raton, Fla.-based cell culture and gene therapy materials company.

Akron founder, CEO and board member Claudia Zylberberg will remain at the helm of the company.

Arcline will work with the company to build out its capabilities and pursue acquisitions in the cell and gene therapy manufacturing tools, ancillary materials and services space.

Arcline has $1.5 billion of capital under management. Its primary areas of interest include life sciences, industrials, technology and specialty chemicals.

Dark Horse Consulting Group advised Arcline on the deal.